EL7.AI
StocksMedium•23 September 2026•
1 min read

Oruka Therapeutics Reports Positive Phase 2a Data for Psoriasis Treatment

Key Facts

1Week 28 data from the EVERLAST-A trial of ORKA-001 showed deepening responses despite no additional dosing after Week 4.
2PASI 100 rates increased to 71.4% and PASI 90 to 87.3% while maintaining a favorable safety profile.

In a move reflecting the rapid evolution of biotechnology for chronic skin diseases, Oruka Therapeutics announced positive Phase 2a results from its EVERLAST-A trial. According to reports, the drug ORKA-001 demonstrated deepening clinical responses through Week 28, despite patients receiving no additional dosing after Week 4. These findings highlight the potential for ORKA-001 to serve as a long-acting treatment for moderate-to-severe plaque psoriasis.

Technical data revealed that PASI 100 response rates increased to 71.4%, while PASI 90 rates reached 87.3%, all while maintaining a favorable safety profile. These developments come as investors monitor the performance of clinical-stage biotechs; per market data, ORKA stock closed at $94.55 on September 22, 2026, after reaching a day high of $96.78.

Looking ahead, the company expects further clinical trial results in late 2026, which could serve as a primary catalyst for the stock. For traders, the $91.53 level (the low from September 22, 2026) represents a near-term technical support point, while focus remains on the company's ability to sustain these efficacy rates in advanced development stages.